[go: up one dir, main page]

NO20072285L - S-mirtazapin for behandling av hetetokter - Google Patents

S-mirtazapin for behandling av hetetokter

Info

Publication number
NO20072285L
NO20072285L NO20072285A NO20072285A NO20072285L NO 20072285 L NO20072285 L NO 20072285L NO 20072285 A NO20072285 A NO 20072285A NO 20072285 A NO20072285 A NO 20072285A NO 20072285 L NO20072285 L NO 20072285L
Authority
NO
Norway
Prior art keywords
mirtazapine
treatment
hot flashes
flashes
hot
Prior art date
Application number
NO20072285A
Other languages
English (en)
Inventor
Bernardus Wijnand Math Peeters
Anton Egbert Peter Adang
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34929859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072285(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organon Nv filed Critical Organon Nv
Publication of NO20072285L publication Critical patent/NO20072285L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Oppfinnelsen tilveiebringer en fremgangsmåte for behandling av hetetokter med S-mirtazapin og anvendelse av S-mirtazapin for fremstilling av et medikament for behandling av hetetokter
NO20072285A 2004-11-15 2007-04-30 S-mirtazapin for behandling av hetetokter NO20072285L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04105778 2004-11-15
PCT/EP2005/055947 WO2006051111A1 (en) 2004-11-15 2005-11-14 S-mirtazapine for the treatment of hot flush

Publications (1)

Publication Number Publication Date
NO20072285L true NO20072285L (no) 2007-06-13

Family

ID=34929859

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072285A NO20072285L (no) 2004-11-15 2007-04-30 S-mirtazapin for behandling av hetetokter

Country Status (30)

Country Link
US (4) US20070265245A1 (no)
EP (1) EP1814555B1 (no)
JP (1) JP2008519810A (no)
KR (1) KR20070085470A (no)
CN (2) CN102772414A (no)
AR (1) AR053780A1 (no)
AT (1) ATE439843T1 (no)
AU (1) AU2005303778B2 (no)
BR (1) BRPI0517818A2 (no)
CA (1) CA2587283C (no)
CY (1) CY1110538T1 (no)
DE (1) DE602005016141D1 (no)
DK (1) DK1814555T3 (no)
ES (1) ES2329815T3 (no)
HR (1) HRP20090513T1 (no)
IL (1) IL182767A (no)
MX (1) MX2007005827A (no)
MY (1) MY144089A (no)
NO (1) NO20072285L (no)
NZ (1) NZ554858A (no)
PE (1) PE20061051A1 (no)
PL (1) PL1814555T3 (no)
PT (1) PT1814555E (no)
RS (1) RS51138B (no)
RU (1) RU2396957C2 (no)
SI (1) SI1814555T1 (no)
TW (1) TW200631584A (no)
UA (1) UA88655C2 (no)
WO (1) WO2006051111A1 (no)
ZA (1) ZA200703884B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002174A2 (en) * 2005-06-27 2007-01-04 N.V. Organon. A method of treatment of hormone depletion induced vasomotor symptoms
US20070129611A1 (en) * 2005-12-06 2007-06-07 University Of North Texas Health Science Center At Fort Worth System, Method and Apparatus for Assessing Menopausal or Post-Hysterectomy Symptoms
EP1993556A1 (en) * 2006-03-06 2008-11-26 N.V. Organon An improved method of weaning from hormonal treatment of hormone depletion induced vasomotor symptoms
MX2009005446A (es) * 2006-11-22 2009-06-02 Organon Nv Sistema de suministro vaginal para mirtazapina.
US7645750B2 (en) 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
JP2009018992A (ja) 2007-07-10 2009-01-29 Sumitomo Chemical Co Ltd 光学活性ミルタザピンの製造方法
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
PL3261645T3 (pl) 2015-02-27 2021-12-06 Dechra Limited Pobudzanie apetytu, zarządzanie utratą masy ciała, i leczenie anoreksji u psów i kotów
MX394876B (es) * 2017-05-25 2025-03-24 Glytech Llc Formulaciones para el tratamiento del trastorno de estres post-traumatico.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
US4515792A (en) * 1982-09-30 1985-05-07 Ciba-Geigy Corporation Tetracyclic heterocycles and antidepressant compositions thereof
JPH1187727A (ja) * 1997-09-12 1999-03-30 Mitsubishi Electric Corp 半導体装置
ES2212550T3 (es) * 1998-04-02 2004-07-16 Akzo Nobel N.V. Solucion oral liquida que comprende el antidepresor mirtazapina.
RU2195951C1 (ru) * 2001-08-20 2003-01-10 Общество с ограниченной ответственностью "Лаборатория "Ирис" Средство для лечения климактерических расстройств

Also Published As

Publication number Publication date
TW200631584A (en) 2006-09-16
HK1104235A1 (en) 2008-01-11
ZA200703884B (en) 2009-07-29
AU2005303778B2 (en) 2011-02-17
MY144089A (en) 2011-08-15
PE20061051A1 (es) 2006-10-26
IL182767A (en) 2011-07-31
CA2587283A1 (en) 2006-05-18
SI1814555T1 (sl) 2009-12-31
CN102772414A (zh) 2012-11-14
PT1814555E (pt) 2009-09-30
CA2587283C (en) 2013-01-15
CN101056641A (zh) 2007-10-17
BRPI0517818A2 (pt) 2010-03-16
CY1110538T1 (el) 2015-04-29
DE602005016141D1 (de) 2009-10-01
RU2396957C2 (ru) 2010-08-20
ATE439843T1 (de) 2009-09-15
HRP20090513T1 (hr) 2009-10-31
UA88655C2 (ru) 2009-11-10
MX2007005827A (es) 2007-07-20
EP1814555B1 (en) 2009-08-19
PL1814555T3 (pl) 2010-01-29
RS51138B (sr) 2010-10-31
AU2005303778A1 (en) 2006-05-18
US20130225559A1 (en) 2013-08-29
US20120302552A1 (en) 2012-11-29
EP1814555A1 (en) 2007-08-08
RU2007122391A (ru) 2008-12-20
ES2329815T3 (es) 2009-12-01
AR053780A1 (es) 2007-05-23
WO2006051111A1 (en) 2006-05-18
IL182767A0 (en) 2007-09-20
JP2008519810A (ja) 2008-06-12
US20100267694A1 (en) 2010-10-21
KR20070085470A (ko) 2007-08-27
US20070265245A1 (en) 2007-11-15
DK1814555T3 (da) 2009-12-07
NZ554858A (en) 2009-10-30

Similar Documents

Publication Publication Date Title
NO20072285L (no) S-mirtazapin for behandling av hetetokter
NO20076206L (no) Kombinasjon av PDE4 inhibitor romflumilast og et tetrahydrobioterin-derivativ
DK1853271T3 (da) Fremgangsmåde og præparat til behandling af perifere vaskulære sygdomme
HUS1500058I1 (hu) Benzoxazint tartalmazó gyógyszer-kombináció légúti betegségek kezelésére
PL2878297T3 (pl) Leki do leczenia lub zapobiegania chorobom zwłóknieniowym
IL179515A0 (en) Method of administering and using vegf inhibitors for the treatment of human cancer
NO20052760D0 (no) Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
DE602005014127D1 (de) Medizinische vorrichtung und herstellungsverfahren dafür
AP2327A (en) Quinoline derivatives for the treatment of latent tuberculosis.
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
NO20070782L (no) Tetrapeptidanaloger.
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
ATE474617T1 (de) Medizinproduktsysteme
EP1799154A4 (en) STENT AND METHOD FOR PRODUCING THE STENT
HRP20150175T1 (en) Means and methods for the treatment of tumorous diseases
IL177490A0 (en) Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
IS7699A (is) Afleiður af díoxan-2-alkýl karbamötum, framleiðslu aðferð þeirra og notkun við meðferð sjúkdóma
NO20050569D0 (no) Fremgangsmate for behandling av alvorlig hjertesvikt og medikament for dette
NO20045554L (no) Fremgangsmate for behandling av diabetes
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
NO20054494L (no) Peptidvektorer
EP1827478A4 (en) METHODS OF TREATING JOINED OR SICK JOINTS
DK1848415T3 (da) Kombinationsterapi med glatirameracetat og rasagilin til behandling af multipel sklerose
DK1670482T4 (da) Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application